The shattering announcement from Pfizer and BioNTech does not mark the end of the vaccine race, far from it. Whatever happens, it seems likely that the global response to the virus will involve an arsenal of several vaccines, not just one. It is in fact not excluded that some may be more effective in the elderly than in the youngest, and vice versa for example. Or that some countries like China or Russia for example prefer to use their own vaccine. Or that the production constraints are too great to satisfy global demand with a single product.
No less than 200 candidates are currently in development and 47 are being tested in humans. Among them, ten are already close to arrival: they are also in phase three, the final validation step which consists of administering the vaccine or a placebo to thousands of participants, in order to demonstrate its possible effectiveness or to detect the occurrence. adverse effects.
It is by